SageView Advisory Group
ARQT icon

SageView Advisory Group’s Arcutis Biotherapeutics ARQT Stock Holding History

SageView Advisory Group’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-47
Closed -$1.36K – 699
2025
Q4 		$1.36K Buy
+47
New +$1.2K ﹤0.01% 2314

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Frazier Life Sciences Management
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Rubric Capital Management (New York)
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Polar Capital Holdings
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

SageView Advisory Group's ARQT Position: Q1 2026 in Review

SageView Advisory Group sold out of Arcutis Biotherapeutics (ARQT) in Q1 2026, closing a stake of 47 shares — an estimated $1.36K sold.

SageView Advisory Group first reported a position in ARQT in Q4 2025 and held it in 1 quarter. The position peaked at $1.36K in Q4 2025. 270 funds tracked by Wall St. Rank hold ARQT as of Q1 2026.

  • SageView Advisory Group reported no remaining Arcutis Biotherapeutics position as of Q1 2026 after selling out during the quarter.
  • SageView Advisory Group sold 47 Arcutis Biotherapeutics shares in Q1 2026, an estimated $1.36K.
  • SageView Advisory Group first reported a position in Arcutis Biotherapeutics in Q4 2025 and held it in 1 quarter.
  • SageView Advisory Group's Arcutis Biotherapeutics position peaked at $1.36K in Q4 2025.
  • 270 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q1 2026.

Based on SageView Advisory Group's 13F filing for Q1 2026, filed 10 Aug 2026.